I. Gibbens

发表

Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial

M. Gore, S. Kaye, C. Rothermundt, 2005, British Journal of Cancer.

Attitudes to chemotherapy in patients with ovarian cancer.

M. Gore, U. Matulonis, F. Dignan, 2004, Gynecologic oncology.

Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial

M. Gore, S. Kaye, C. Rothermundt, 2005, British Journal of Cancer.

A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer

M. Gore, G. Hall, R. A’Hern, 2004, British Journal of Cancer.

Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients

M. Gore, R. Marais, B. Schwartz, 2005 .

A Phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma

J. Larkin, M. Gore, P. Patel, 2006, British Journal of Cancer.

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

M. Ratain, K. Flaherty, M. Gore, 2006, British Journal of Cancer.

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies

M. Gore, P. Nathan, R. Marais, 2011, British Journal of Cancer.